Skip to main content

Tumor acidosis

Cancer cells tend to turn their extracellular environment acidic, thus helping these rogue cells thrive while creating a hostile environment for normal ones. Acidosis promotes tumor growth, metastasis and drug resistance, while helping tumor cells evade the immune system. But it’s not clear exactly how this occurs. 

 Using a fluorescently-labeled peptide called pHLIP that only inserts itself into the membranes of cells under acidic conditions, they mapped the acidic regions of mammary tumors produced by human breast cancer cell lines in mice. The pH probe provided striking images, for the first time at cell-level resolution, that confirmed what previous methods had suggested: acidosis is not confined to the hypoxic tumor core, but rather extends to the boundary between tumors and healthy tissue. Called the tumor-stroma interface, this boundary is the advancing edge of a malignant tumor, where cells spread aggressively and break into blood vessels and nearby healthy tissues. Again using fluorescent markers, the researchers found that the acidic regions displayed signatures of tumor invasiveness: increased expression of matrix metalloproteases in the cells at the acidic tumor-stroma interface as well as degradation of the basement membrane surrounding healthy tissues.

 It revealed that the majority of cells at the interface were carrying out glycolysis, a type of metabolism that perpetuates an acidic environment. Hypoxia, or low oxygen, can force cells to resort to anaerobic glycolysis; however, glycolysis was occurring at the tumor-stroma interface even in the presence of oxygen. Together, the results suggest that aerobic glycolysis may be a primary driver of acidosis at the interface, spurring cells to invade. “The next logical steps would be looking into the causes of tumor acidity that are independent of glycolysis and hypoxia because it’s still relatively unknown,” says Ian Robey, a tumor biologist at the University of Arizona Cancer Center who was not involved with the research.

n the study, when researchers fed sodium bicarbonate (baking soda) to mice with mammary or lung tumors, the tumor boundaries became less acidic and the proliferative and metastatic signatures of the tumor cells decreased. “It adds to the sense that this pH dynamic is not permanent. It’s reversible,” Robey says. “I think that’s an important addition to an ongoing discussion about the role of pH in tumor behavior.”
While baking soda may not be a realistic treatment for humans, clinical trials are currently testing nanoparticles and other agents that zero in on the low pH environment surrounding solid tumors and raise extracellular pH in an attempt to shut down metastasis. “It’s an exciting possibility to essentially have pH-sensitive therapeutics that that might become active upon encountering the acidity of the microenvironment,” adds Gertler.
Gertler and study coauthor Nazanin Rohani, now a cell biologist at the National Research Council Canada in Montreal, say that future work will focus on investigating whether the pH-induced transcriptional changes their team observed can explain the mechanisms underlying metastasis and possibly identify new therapeutic targets.

Reference:
Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes
Nazanin RohaniLiangliang HaoMaria S AlexisBrian A JoughinKonstantin KrismerMira N MoufarrejAnthony R SoltisDouglas A. LauffenburgerMichael B. YaffeChristopher B BurgeSangeeta N. Bhatiaand Frank B. Gertler

Comments

Popular posts from this blog

Mounjaro, Is it a game changer for weight loss and diabetes?

  MOUNJARO™ ( Tirzepatide) was approved for medical use in the United States in May 2022 WEIGHT LOSS: (Not approved by FDA for weight loss) Eli Lilly and Company is  finalizing an application to the U.S. Food and Drug Administration for fast-track approval to sell tirzepatide for chronic weight management. MOUNJARO™ is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in adults for type 2 diabetes mellitus management. CONTRAINDICATIONS Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2  Known serious all to tirzepatide or any of the excipients in MOUNJARO                                                                    ...

Thyroid health- Quality of Life

  Let's get a TSH blood test for our family and friends Normal serum TSH ranges are higher in the  people age 70 to 80 years ; based on this, higher serum TSH goals may be needed as a patient ages.  The American Thyroid Association (ATA) suggests raising the target serum TSH to 4-6 m IU/L for 70 years-old and up The thyroid is a small, butterfly-shaped hormone-producing gland located at the front of the neck. The thyroid gland secretes two main hormones:  thyroxine (T-4) and triiodothyronine (T-3).   These hormones regulate energy levels, metabolism of fats, proteins and carbohydrates, body temperature, heart rate.  Hypothyroidism happens when the underactive thyroid gland doesn't make enough hormones. Hypothyroidism affects up to 10% of the general population (5% undiagnosed) . A n autoimmune disease called Hashimoto's diseas e where our body  makes antibodies that attack healthy thyroid tissues  is the most common cause of hypothyroidism in soc...

Heart healthy

*Clinical atherosclerotic cardiovascular disease (ASCVD) includes acute coronary syndrome (ACS), those with history of myocardial infarction (MI), stable or unstable angina or coronary or other arterial revascularization, stroke, transient ischemic attack (TIA), or peripheral artery disease (PAD) including aortic aneurysm, all of atherosclerotic origin. Should I initiate statins or not? The 2014 National Lipid Association (NLA) recommendations provides a more comprehensive, patient-centered approach to identifying ASCVD risk.   In 2013, the American College of Cardiology and the American Heart Association (ACC/AHA) issued guidelines to use the intensity of statin therapy as the treatment goal instead of LDL-C or non–HDL-C targets, as in previous guidelines, to reduce atherosclerotic cardiovascular disease (ASCVD) risk (  Andrus & Lacaille, 2014  )  The guideline classifies statin therapy as  high-intensity (lowers LD...